ArticleScientific reports2017
A network-based method for mechanistic investigation of Shexiang Baoxin Pill's treatment of cardiovascular diseases.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Efficacy and safety of Shexiang Baoxin Pill for stable coronary artery disease: A systematic review and meta-analysis of 42 randomized controlled trials.Frontiers in pharmacology · 2022Pooled it
- Meta-analysis and trial sequential analysis of shexiang baoxin pill for coronary slow flow.Frontiers in pharmacology · 2022Pooled it
- Pooled it
- Trial
- Comparative Proteomic Profiling and Biomarker Identification of Traditional Chinese Medicine-Based HIV/AIDS Syndromes.Scientific reports · 2018Trial
- Impact of Shexiang Baoxin Pill (MUSKARDIA) on Cardiovascular Outcomes by Baseline Hemoglobin Levels in 2,494 Patients with Chronic Stable Coronary Artery Disease: A Secondary Subgroup Analysis.Chinese journal of integrative medicine · 2026Article
- Polypharmacological Exploration of Petroselinum Crispum for Antifibrotic Therapeutics: from Herb to Hepatoprotection.Applied biochemistry and biotechnology · 2026Article
- Therapeutic efficacy and safety of Shexiang Baoxin Pill in relation to anxiety and depression in patients with coronary heart disease.Medicine · 2026Article
- Effects of Shexiang Baoxin pill combined with exercise rehabilitation training on long-term prognosis of CTO-PCI patients: study protocol for randomized controlled trial.Frontiers in medicine · 2025Article
- Berberine alleviates atherosclerosis by modulating autophagy and inflammation through the RAGE-NF-κB pathway.Frontiers in pharmacology · 2025Article
- The antidepressant effect of Shexiang Baoxin Pills on myocardial infarction rats with depression may be achieved through the inhibition of the NLRP3 inflammasome pathway.Brain and behavior · 2024Article
- Article
- Integration of serum metabolomics and network pharmacology reveals the immunoenhancing mechanisms of Qishenbuqi capsules.Toxicology research · 2023Article
- Identification of phytochemical compounds ofHeliyon · 2023Article
- Discussion on the Mechanism of Gandoufumu Decoction Attenuates Liver Damage of Wilson's Disease by Inhibiting Autophagy through the PI3K/Akt/mTOR Pathway Based on Network Pharmacology and Experimental Verification.Mediators of inflammation · 2023Article
- Single-nucleus ribonucleic acid-sequencing and spatial transcriptomics reveal the cardioprotection of Shexiang Baoxin Pill (SBP) in mice with myocardial ischemia-reperfusion injury.Frontiers in pharmacology · 2023Article
- Exploring the Mechanism of Hawthorn Leaves Against Coronary Heart Disease Using Network Pharmacology and Molecular Docking.Frontiers in cardiovascular medicine · 2022Article
- Shexiang Baoxin Pill (MUSKARDIA) reduces major adverse cardiovascular events in women with stable coronary artery disease: A subgroup analysis of a phase IV randomized clinical trial.Frontiers in cardiovascular medicine · 2022Article
- Application of metabolomics and network analysis to reveal the ameliorating effect of four typical "hot" property herbs on hypothyroidism rats.Frontiers in pharmacology · 2022Article
- Effects of 6-Hydroxykaempferol: A Potential Natural Product for Amelioration of Tendon Impairment.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Shexiang Baoxin Pill (SBP), a traditional Chinese medicine formula, is commonly used to treat cardiovascular disease (CVD) in China. However, the complexity of composition and targets has deterred our understanding of its mechanism of action. Using network pharmacology-based approaches, we established the mechanism of action for SBP to treat CVD by analyzing protein-protein interactions and pathways. The computational results were confirmed at the gene expression level in microarray-based studies. Two of the SBP's targets were further confirmed at the protein level by Western blot. In addition, we validated the theory that SBP's plasma absorbed compounds play major therapeutic role in treating CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.